A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


August 1, 2012

Toward a Cure: Virologic Control Documented in 14 Acute HIV Treaters

by Tim Horn

AIDS 2012A new study released Thursday, July 26, at the XIX International AIDS Conference (AIDS 2012) in Washington, DC, found that 14 people living with HIV have achieved long-term non-progressing “viral controller” status after being treated with antiretrovirals (ARVs) during the acute phase of their infections. The fact that these individuals have shown no signs of viral load rebounds following termination of their prescribed treatment regimens may ultimately provide guidance to scientists pursuing “functional” HIV cures.

The 14 individuals described at AIDS 2012 by Charline Bacchus, PhD, of the French National Agency for Research on AIDS and Viral Hepatitis (ANRS) comprise the Virologic and Immunologic Studies in Controllers after Treatment Interruption (VISCONTI) cohort.

VISCONTI participants initiated ARV therapy within ten weeks of becoming infected with HIV and remained on treatment for roughly three years. They averaged 500 CD4 cells and viral loads of 100,000 copies upon starting treatment. Roughly six-and-a-half years after stopping treatment, the average CD4 cell count was 900 and all study subjects had viral loads below 50 copies.

"Six years after interruption of treatment, patients treated early on in the post-infection period present a perfect ability to control the HIV infection,” Bacchus said. She added that VISCONTI cohort participants also possess an extremely small reservoir of HIV in CD4 cells, similar to levels seen in “elite controllers” who spontaneously reduce their viral loads to undetectable levels without treatment.

Could it be that VISCONTI cohort participants would have been elite controllers without the use of ARVs? Not likely, Bacchus explained, as the patients’ human leukocyte (HLA) patterns—the genes related to immune function in humans—differ from those seen in individuals participating in untreated virologic controller cohorts.   

Bacchus noted that research is ongoing to explore the immunologic characteristics that allowed these patients to remain off treatment, without viral load rebounds.

Search: visconti, french, anrs, bacchus, functional cure, acute infection, treatment, arvs, aids 2012

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (14 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.